Massive Rotator Cuff TearNCT07208448
Voll Degradable Shoulder Spacer FIH Study
A study testing Voll Degradable Shoulder Spacer in people with Massive Rotator Cuff Tear, run by Voll Medical Technologies Ltd. at 4 sites in 2 countries.
Trial summary
The Voll Degradable Shoulder Spacer First-in-Human study aims to evaluate the initial safety, effectiveness, and clinical outcomes of a degradable shoulder spacer in over 50 years old patients with symptomatic massive rotator cuff tears (MRCT). Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Massive Rotator Cuff Tear
- What is being tested?
- Voll Degradable Shoulder Spacer
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 4 sitesin 2 countries
- Study dates
- 9 Dec 2025to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Main Inclusion Criteria:
- Full thickness MRCT.
- Male or female patients ≥ fifty (50) years of age, in general good health, independent, and can comply with all post-operative evaluations and visits.
Main Exclusion Criteria:
- Documented evidence of a history of drug/alcohol abuse within 1 year of enrollment.
- Concurrent participation in any other investigational clinical study.
Trial locations and contacts
4 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
4 sites in 2 countries
Israel2 sites, 2 recruiting
- Recruiting
Assuta Ashdod Hospital
Ashdod
Sahar Boostenay, +97254421243, sahar@vollmedical.com
Ran Atzmon, MD
- Not yet recruiting
Ichilov (Sourasky Medical Center)
Tel Aviv
Sahar Boostenay, +972544621243, sahar@vollmedical.com
Efi Kazum, MD
Italy2 sites, 2 recruiting
- Recruiting
Humanitas Gavazzeni Castelli
Bergamo, Bergamo, 24125
Sahar Boostenay, +972544621243, saharb@vollmedical.com
Vincenzo Condello, MD
- Recruiting
Istituto Ortopedico Rizzoli
Bologna, Bologna, 40136
Sahar Boostenay, +972544621243, saharb@vollmedical.com
Stefano Zaffagnini, Prof.
About this study
Official title: A Multi-Center, Prospective, First-In-Human Study to Evaluate the Initial Safety and Effectiveness of a Degradable Shoulder Spacer in Patients With Symptomatic Massive Rotator Cuff Tears
The Voll Degradable Shoulder Spacer First-in-Human study aims to evaluate the initial safety, effectiveness, and clinical outcomes of a degradable shoulder spacer in over 50 years old patients with symptomatic massive rotator cuff tears (MRCT).
- Conditions
- Massive Rotator Cuff Tear
- Being tested
- Voll Degradable Shoulder Spacer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Voll Degradable Shoulder SpacerDevice
Voll Degradable Shoulder Spacer
| Study group | Role | What they receive |
|---|---|---|
| Voll Degradable Shoulder Spacer | Experimental | Not described Receives: Device: Voll Degradable Shoulder Spacer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Device-related Serious Adverse Events
Incidence of device-related serious adverse events (DRSAEs) related to the spacer.
Measured: Up to 12 months post-implantationץ
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2025
- Study start9 Dec 2025
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Massive Rotator Cuff TearStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Voll Medical Technologies Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07208448
- Sponsor's protocol ID
- 053CLD
- Status last verified
- Jul 2026
- First submitted
- 18 Sep 2025
- Last updated
- 30 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-Center, Prospective, First-In-Human Study to Evaluate the Initial Safety and Effectiveness of a Degradable Shoulder Spacer in Patients With Symptomatic Massive Rotator Cuff Tears
- ClinicalTrials.gov ID
- NCT07208448
- Acronym / sponsor ID
- 053CLD
- Conditions
- Massive Rotator Cuff Tear
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Voll Medical Technologies Ltd.Industry (pharma, biotech, devices)
- Study start
- 9 Dec 2025 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 6 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Voll Degradable Shoulder Spacer First-in-Human study aims to evaluate the initial safety, effectiveness, and clinical outcomes of a degradable shoulder spacer in over 50 years old patients with symptomatic massive rotator cuff tears (MRCT).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Voll Degradable Shoulder Spacer | Experimental | Device: Voll Degradable Shoulder Spacer |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Voll Degradable Shoulder SpacerVoll Degradable Shoulder Spacer | Device | Voll Degradable Shoulder Spacer |
Primary outcome
Device-related Serious Adverse Events
Time frame: Up to 12 months post-implantationץ
Incidence of device-related serious adverse events (DRSAEs) related to the spacer.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Massive Rotator Cuff Tear
Recruiting
Arthroscopic Rotator Cuff Repair With Long Head of Biceps Transposition and Acellular Dermal Matrix Augmentation for Large to Massive Incompletely Repairable Rotator Cuff Tears
Rotator Cuff Tears, Rotator Cuff Injuries
Recruiting
Effects Of Biceps Transposition Without Tenotomy For Augmentation Of Massive Rotator Cuff Repairs
Massive Rotator Cuff Tear
Active, not recruitingObservational study
Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study
Rotator Cuff Tears, Rheumatoid Arthritis Shoulder
Not yet recruiting
Voll Non-Degradable Shoulder Spacer FIH Study
Massive Rotator Cuff Tears, Massive Rotator Cuff Tear
Recruiting
Superior Capsular Reconstruction vs. Partial Repair for Massive Rotator Cuff Tears
Rotator Cuff Tear
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
4 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Voll Degradable Shoulder Spacer in people with Massive Rotator Cuff Tear, run by Voll Medical Technologies Ltd. at 4 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Israel, Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Device-related Serious Adverse Events (time frame: Up to 12 months post-implantationץ). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026.